A prospective study evaluating Host Factors That Predict the Therapeutic Effect of Nintedanib for Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 12 Jul 2023
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 24 May 2023 Results examining the efficacy of nintedanib in patients with IPF using clinical information and to determine the variability of treatment response over a 2-year period presented at the 119th International Conference of the American Thoracic Society
- 27 Jun 2021 New trial record
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society